Skip to Content

Join the 'Seizures' group to help and get support from people like you.

Seizures News

Related terms: Complex Partial Seizure, Fits, Absence Seizure

Epilepsy Linked to Risks During Childbirth, Study Finds

Posted 6 Jul 2015 by Drugs.com

MONDAY, July 6, 2015 – Pregnant women with epilepsy may have more than a higher risk of dying during delivery, a new study suggests. "Specifically, there were 80 deaths per 100,000 women with epilepsy versus six deaths per 100,000 in women without epilepsy," said lead researcher Sarah MacDonald, from the department of epidemiology at Harvard T.H. Chan School of Public Health in Boston. However, although the so-called "relative risk" of death during delivery among women with epilepsy was high, it's still a rare occurrence, MacDonald stressed. The researchers also found that the risk of delivery complications was higher among women with epilepsy. "We also found that women with epilepsy were at increased risk for cesarean delivery, prolonged hospital stay, preeclampsia [pregnancy-related high blood pressure], preterm labor and stillbirth," she said. Although the study found a link between ... Read more

Related support groups: Seizures, Epilepsy, Seizure Prevention, Delivery, Seizure Prophylaxis, Premature Labor, Labor Induction, Labor and Delivery including Augmentation

FDA Approves Fycompa as Adjunctive Treatment for Primary Generalized Tonic-Clonic Seizures

Posted 30 Jun 2015 by Drugs.com

Tokyo, June 22, 2015 – Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an indication expansion regarding the use of its in-house developed antiepileptic agent Fycompa (perampanel hydrate) as an adjunctive treatment of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy 12 years of age and older. The FDA's decision to approve the indication expansion was based on a placebo-controlled clinical phase III study (Study 332) of Fycompa in 164 patients aged 12 years and older with PGTC seizures. In the study, a statistically significant reduction in PGTC seizure frequency was observed in the Fycompa group compared with placebo (Fycompa: -76.5%, placebo: -38.4%, p Read more

Related support groups: Seizures, Epilepsy, Seizure, Fycompa, Perampanel

Online Community Helps People Manage Epilepsy

Posted 17 Jun 2015 by Drugs.com

WEDNESDAY, June 17, 2015 – Being part of an online community may help people with epilepsy better manage their disease, a new study suggests. "Epilepsy is a complicated disease, and many people who live with it are not well informed about their condition and how to manage it. Formal, in-person education can be expensive and difficult to coordinate, especially when people live in rural areas. We wanted to see whether an online community could benefit people with epilepsy," study author Dr. John Hixson, of the University of California San Francisco and the San Francisco VA Medical Center, said in a news release from the journal Neurology. The research included almost 100 epilepsy patients who participated in an online forum called PatientsLikeMe. In the forum, people with epilepsy can share information and support. It also has digital tools for tracking seizures, symptoms and ... Read more

Related support groups: Seizures, Epilepsy, Seizure Prevention, Seizure Prophylaxis

FDA Medwatch Alert: Potiga (ezogabine): Drug Safety Communication - FDA Determines 2013 Labeling Adequate to Manage Risks of Retinal Abnormalities, Potential Vision Loss, and Skin Discoloration

Posted 16 Jun 2015 by Drugs.com

ISSUE: Based on reviews of additional safety reports from patients treated with the anti-seizure drug Potiga (ezogabine), the FDA has determined that the potential risks of vision loss due to pigment changes in the retina and of skin discoloration can be adequately managed by following the current recommendations in the Potiga labeling. To further explore any potential long-term consequences of these pigment changes, FDA has required the Potiga manufacturer, GlaxoSmithKline, to conduct a long-term observational study. FDA review of additional safety reports does not indicate that the pigment changes in the retina observed in some patients affect vision. Skin discoloration associated with the use of Potiga appears to be a cosmetic effect and does not appear to be associated with more serious adverse effects. Therefore, a modification of the Risk Evaluation and Mitigation Strategy (REMS) ... Read more

Related support groups: Seizures, Potiga, Ezogabine

FDA Approves Expanded Indication for Qudexy XR (Topiramate) for Pediatric Patients

Posted 3 Jun 2015 by Drugs.com

Maple Grove, MN – June 1, 2015 – Upsher-Smith Laboratories, Inc. (Upsher-Smith) announced that it has received U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) for Qudexy XR (topiramate) extended-release capsules for use as initial monotherapy in patients two years of age and older who are experiencing partial-onset seizures (POS) or primary generalized tonic-clonic seizures. Qudexy XR capsules are the only once-daily extended-release topiramate product to have received this expanded indication and to be approved for administration by sprinkling their contents onto soft food, making them a useful option for young children who may have difficulty swallowing whole capsules or tablets. Qudexy XR is a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth pharmacokinetic profile. “The expanded indication give ... Read more

Related support groups: Seizures, Topiramate

Health Tip: Travel Safely in the Air

Posted 12 May 2015 by Drugs.com

-- A little preparation can help you stay healthy and safe when traveling by plane. The American Academy of Family Physicians recommends: Packing all necessary medications in a carry-on bag. Talk to your doctor about whether you should change your medication regimen while traveling. Pack some extras, in case your trip is extended. If you have a chronic illness such as epilepsy or diabetes, carry an identification card with your doctor's contact information and a list of your medications. Drink non-alcoholic, no-caffeine beverages to avoid dehydration. If you tend to have ear pain, take a decongestant before you fly, or chew gum. Stretch calves frequently, and walk around when it is safe to do so. Read more

Related support groups: Diabetes, Type 2, Seizures, Epilepsy, Seizure Prevention, Diabetes, Type 1, Dehydration, Seizure Prophylaxis, Diabetes Mellitus

High-Pitched Sounds May Trigger Seizures in Cats

Posted 28 Apr 2015 by Drugs.com

TUESDAY, April 28, 2015 – High-pitched sounds may trigger seizures in cats, particularly older felines, a new study says. Although many veterinarians are unaware of this connection, the louder the sound, the more severe the seizure, British researchers contend. Cat owners around the world were surveyed by scientists at University College London's School of Pharmacy, to find out if their pets had seizures or involuntary jerking motions in response to certain sounds. The researchers found hundreds of people noticed this behavior in their cats. They also found local vets had no answers for why cats reacted this way. The researchers compiled detailed information on 96 cats, including the type of seizures they had, how long they lasted, and the sound that seemed to trigger the reaction. The study, published April 27 in the Journal of Feline Medicine and Surgery, found some cats do seemingly ... Read more

Related support groups: Seizures, Keppra, Seizure Prevention, Levetiracetam, Seizure Prophylaxis, Keppra XR

Medical Groups Issue Guidelines for Treating First Seizure

Posted 20 Apr 2015 by Drugs.com

MONDAY, April 20, 2015 – One in 10 people worldwide will have a seizure in his or her lifetime, experts say. Now, two medical groups have issued a new guideline on how to treat them. The decision to treat a patient after a first seizure is complex because doctors must weigh the risks and benefits on an individual basis, according to the American Academy of Neurology and the American Epilepsy Society. After a review of all available evidence, the two organizations concluded that taking epilepsy drugs immediately after a first seizure may reduce the risk of more seizures. The guideline, published in the April 21 issue of the journal Neurology, will be presented this week at the annual meeting of the American Academy of Neurology, in Washington, D.C. "This is a valuable new guideline that could change the approach many doctors take to treating a first seizure and could improve patients' ... Read more

Related support groups: Seizures, Seizure Prevention, Seizure Prophylaxis

Liquid Medical Marijuana Shows Promise Against Severe Epilepsy

Posted 13 Apr 2015 by Drugs.com

MONDAY, April 13, 2015 – A liquid form of medical marijuana may help people with severe epilepsy that does not respond to other treatments, according to a new report. The study included 213 child and adult patients with 12 different types of severe epilepsy. Some of them had Dravet syndrome and Lennox-Gastaut syndrome, which are types of epilepsy that can cause intellectual disability and lifelong seizures. The patients took a liquid form of medical marijuana, called cannabidiol, daily for 12 weeks. Among the 137 people who completed the study, the number of seizures fell by an average of 54 percent, according to a team led by Dr. Orrin Devinsky, of New York University Langone Comprehensive Epilepsy Center in New York City. Among the 23 patients with Dravet syndrome who completed the study, the number of convulsive seizures fell by 53 percent, the investigators found. The 11 patients ... Read more

Related support groups: Seizures, Epilepsy, Seizure Prevention, Seizure Prophylaxis

Too Few Kids With Epilepsy, Cerebral Palsy Get Flu Shot: Study

Posted 10 Apr 2015 by Drugs.com

FRIDAY, April 10, 2015 – Children with neurological disorders such as epilepsy or cerebral palsy are at increased risk for complications from the flu, but are no more likely to receive a flu shot than other kids are, a new U.S. study shows. It's possible that many doctors don't know that some of these disorders put children at increased risk for flu-related complications, the researchers said. "Our research shows that influenza vaccination in children with [neurological disorders] is comparable to vaccination in healthy children – but both rates are suboptimal," study author Dr. Michael Smith, a pediatric infectious disease specialist at the University of Louisville, said in a university news release. "More education about the need for annual influenza vaccination is needed, both for parents and health care providers," he added. The researchers conducted a nationwide survey of more ... Read more

Related support groups: Seizures, Influenza, Epilepsy, Cerebral Palsy, Vaccination and Prophlaxis, Influenza Prophylaxis

SPARC Announces FDA Approval of Elepsia XR (levetiracetam) Extended-Release Tablets

Posted 4 Mar 2015 by Drugs.com

March 04, 2015, Mumbai: Sun Pharma Advanced Research Company Ltd. (SPARC) today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Elepsia XR (Levetiracetam extended-release tablets 1000 mg and 1500 mg). Elepsia XR is indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy. “Levetiracetam is a very successful and highly effective antiepileptic drug but more than 80% of epilepsy patients require Levetiracetam in does in range of 1000mg to 3000mg resulting in a significant pill burden. Approval of Elepsia XR as 1000mg and 1500mg once a day tablets will be very useful for these patients and physicians.” said Anil Raghavan, Chief Executive Officer of SPARC. The product will be manufactured by Sun Pharmaceutical Industries Ltd at its Halol (Gujarat) facility in Ind ... Read more

Related support groups: Seizures, Epilepsy, Levetiracetam

Epilepsy Surgery Gets High Marks From Patients in Survey

Posted 26 Feb 2015 by Drugs.com

THURSDAY, Feb. 26, 2015 – More than nine in 10 epilepsy patients who had brain surgery to try to control their seizures are happy they did so, a new survey reveals. The review appears to be driven by the fact that patients saw the number of debilitating seizures they experienced after surgery either drop significantly or disappear altogether, the researchers noted. "One percent of the U.S. population has epilepsy, and among that group there are about 750,000 patients with recurring seizures that are not well-controlled," said study co-author Dr. Marianna Spanaki-Varelas, director of the Henry Ford Comprehensive Epilepsy Program at Henry Ford Hospital in Detroit. "Of those, 30 to 35 percent are [surgical] candidates because they do not respond to the roughly 15 appropriate epilepsy drugs that we have." A great majority of those who have surgery say it was worthwhile because many remain ... Read more

Related support groups: Seizures, Epilepsy, Seizure Prevention, Seizure Prophylaxis

Eisai Receives Approval for Antiepileptic Drug Banzel (rufinamide) As Adjunctive Treatment For Pediatric Patients

Posted 15 Feb 2015 by Drugs.com

Tokyo, Japan – February 16, 2015 – Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has received approval of an additional pediatric indication for Eisai’s antiepileptic drug (AED) Banzel (rufinamide) from the U.S. Food and Drug Administration (FDA). Through this approval, Banzel, which had been approved for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children four years older and adults, is now additionally approved for the same indication in pediatric patients from one to less than four years of age in the United States. The additional indication approval is based on an interim analysis of a Phase III clinical trial (Study 303) in pediatric patients from one to less than four years of age comparing Banzel with other existing AEDs as add-on treatments. The study showed that the pharmacokinetic and safety profiles are c ... Read more

Related support groups: Seizures, Banzel, Lennox-Gastaut Syndrome, Rufinamide

Two Drugs Work Equally Well for Epileptic Seizures in Kids: Study

Posted 22 Apr 2014 by Drugs.com

TUESDAY, April 22, 2014 – Researchers comparing two drugs used to treat epileptic seizures in children – lorazepam (Ativan) and diazepam (Valium) – found no difference between them in safety or effectiveness. Although previous studies gave the edge to Ativan, Dr. James Chamberlain, lead researcher for the new study, gave several reasons why Valium might be as good or better. "Unexpectedly, Ativan is not superior to Valium for treating pediatric seizures. It's been dogma in medicine that Ativan is better than Valium, but this study shows that they are just about equal," said Chamberlain, division chief of emergency medicine and trauma services at Children's National Medical Center in Washington, D.C. Since Valium does not have to be refrigerated, it might be a better choice for paramedics who treat seizure patients before they arrive at a hospital, he said. "They can start Valium ... Read more

Related support groups: Seizures, Ativan, Valium, Lorazepam, Epilepsy, Diazepam, Diastat, Valrelease, Lorazepam Intensol, Dizac, Diastat AcuDial, Diazepam Intensol, Zetran, Diastat Pediatric

Upsher-Smith Receives FDA Approval for Qudexy XR (topiramate) Extended-Release Capsules

Posted 13 Mar 2014 by Drugs.com

Maple Grove, MN – March 12, 2014 – Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced it received approval on March 11, 2014 from the U.S. Food and Drug Administration (FDA) for Qudexy XR (topiramate) extended-release capsules, a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth pharmacokinetic (PK) profile. Qudexy XR is indicated as initial monotherapy in patients 10 years of age and older with partial-onset seizures (POS) or primary generalized tonic clonic seizures. It is also approved as adjunctive therapy in patients 2 years of age and older with POS, primary generalized tonic-clonic seizures and seizures associated with Lennox-Gastaut syndrome. Qudexy XR will be available to patients in the second quarter of 2014. As many as two out of three patients treated for epilepsy have seizures that are refractory to therapy, either bec ... Read more

Related support groups: Seizures, Topiramate

Page 1 2 3 4 Next

Ask a Question

Further Information

Related Condition Support Groups

Seizure Prevention, Seizure Prophylaxis, Epilepsy

Related Drug Support Groups

Valium, diazepam, Keppra, Dilantin, Trileptal, progesterone, phenobarbital, levetiracetam, phenytoin, view more... oxcarbazepine, Vimpat, zonisamide, primidone, Zonegran, valproic acid, Keppra XR, pyridoxine, Depakene, Vitamin B6, Zarontin, Mysoline, lacosamide, Fycompa, Phenytoin Sodium, Potiga, ethosuximide, Aptiom, Stavzor, Sabril, Pentothal, Oxtellar XR, vigabatrin, Diastat, Gabitril, Valrelease, Luminal, Phenytek, perampanel, thiopental, Depacon, trimethadione, ezogabine, Elepsia XR, Aminoxin, tiagabine, methsuximide, paramethadione, ethotoin, Vitelle Nestrex, eslicarbazepine, Peganone, Dizac, Diastat AcuDial, Celontin, Zetran, Diastat Pediatric, Paradione, Diazepam Intensol, Nestrex, Solfoton, Tridione